Sopheon Share Discussion Threads

[battlebus2] 09/11/2017 23:04

Are we not already with BASF. Broker reiterated buy and £6 target today 👍

[trinko] 09/11/2017 22:50

Strange after hours 15000 sold at 3.60 tomorrow up??

[janeann] 09/11/2017 07:23

well certis is a relatively small player in the crop protection arena; perhaps spe could go after the bigger players - the basf bayer duponts &Syngenta etc

[trinko] 09/11/2017 07:17

Some news, good me things

Certis Europe Partners with Sopheon to Drive Growth and Innovation Ambitions

Sopheon’s Accolade software aligns business growth strategy with external market needs and operational cross-functional budgets

Sopheon, the international provider of software, expertise, and best practices for Enterprise Innovation Performance, today shared that Certis Europe, an established crop protection business, is well underway with its transformation from a stand-alone innovation and development process to a more market-driven operating model with the help of Sopheon’s Accolade® software solution.

“The Accolade application is improving our focus on growth projects aligned to the market needs as well as our efficiency in development and bringing new products to market,” said Certis Europe Head of Portfolio, Jennifer Lewis. “We see it as an important tool that will underpin our future growth strategy.”
Certis Europe is a European crop protection specialist focusing on the development, registration and distribution of products based on unique and patented active ingredients from its Japanese shareholders. Two years ago, Certis Europe set out to transform its development activities from a country by country approach to one that is more collaborative and portfolio (product group) focused. This was fueled by a desire to streamline their new product research and multi-country product registration processes, thereby reducing complexity, making them less time intensive, increasing efficiency, and ensuring a combination of operational and commercial excellence. The outcome has been increased revenues and growth in market share.

Sopheon’s Accolade software, branded internally as AToM (“Advance To Market”) is playing a key role in Certis’ company transition. It is streamlining innovation processes and the collaboration between the different functions within the company. The system serves as the central corporate repository for all Development and Registration Projects, and is used to prioritize and manage this portfolio in close alignment with Product Line (Portfolio) Teams and markets and countries in which they are sold. Without the transparency enabled by the software for decision making by the various business functions, this new operating model would not be possible. Accolade is now integral to day to day work within the business, being used throughout the company within marketing, development and country functions.

Sopheon® and Accolade® are trademarks of Sopheon.

[runthejoules] 08/11/2017 00:19

Actually samsj I did! Hope you did too. And a bit of TAP which was less impressive. Might spread bet this lightly, as a hedge.

[samsj] 07/11/2017 18:53

Hope you took VRS :) January is TU to Dec 31, two months to go

[runthejoules] 02/11/2017 20:02

Is there a TU due anytime soon? Can't find anything on Stockopedia. Thinking of transferring this into £VRS.

[5oletrader] 19/10/2017 11:55

Sopheon Awarded Funding for European Research Projects

Funding recognizes Sopheon’s ongoing contribution to research on market disruptors such as Internet of Things, real-time decision support, and advanced analytics embedded into business process

Sopheon, the international provider of software, expertise, and best practices for Enterprise Innovation Performance, today announced the award of European funding for innovative research in the framework of the EUREKA/ITEA research program alongside a consortium of project partners. The funding is for two different projects, Medolution and PARTNER.

Both research projects focus on developing innovative and intelligent methods and software for real time handling of massive volumes of data across complex scenarios, with emphasis on the healthcare industry. Sopheon’s contribution to these projects focuses on applying the data-driven decision support capabilities of our Accolade® software. Sopheon benefits in return from the collaboration with project partners − research institutes and leading software companies such as Philips Healthcare, Atos/Bull, Siemens Healthcare, Barco, IMEC, KPN and NXP Semiconductors – to develop breakthrough capabilities for commercial application in our software.

In the current digital age, organizations are looking for technologies that allow them to handle unprecedented amounts of information, with speed. This information is drawn from a very incoherent landscape of IT systems and sources, within as well as beyond the physical boundaries of the enterprise. The data to be handled comes from many different sources – structured and unstructured data; metadata from sensor data, images, video – and is reused in the context of big data analysis, internet of things (IoT) techniques, cloud services, etc.

The Accolade software is able to interpret all of this data in real time, irrespective of source or format, based on rules and criteria defined by domain experts and within predefined best practice protocols that are managed by the Accolade system.

Huub Rutten, VP Research and Application Development at Sopheon, stated:

“For Sopheon the research is very applicable to our core enterprise innovation management clients and future product strategy. Our work in these projects positions us to develop relationships with some of the leading companies in the world for commercial leverage, and to develop innovative strategic technologies and applications for our target markets. Further, our research discoveries also have the potential to open new market segments for our application.”
This award brings to a total of five the number of research grants awarded to Sopheon since 2009

[samsj] 11/10/2017 13:04

"a growing sales pipeline, including several blue chip companies representing major enterprise opportunities" "In addition" to revenue visibility of 20.3m

Second half and especially fourth quarter for Sopheon always risks being "very strong" for Sopheon so hopefully good chance of January update being good.

Mence's 458,326 shares is approaching 6m GBP and doesn't include the loan stock of 640,000 gbp with conversion price 76.5p. Also question of who owns BVI company Rivomore and Myrtledare which have 1,608,500 shares and another 640,000 gbp of loan stock at 76.5p. Could Mence alone end up with 15m gbp worth of stock at current prices or my calcs wrong?

[chadders] 11/10/2017 11:31

Good to see director buys. Not huge amounts but still a positive sign. Moving shares to tax free wrappers also positive methinks.

[chadders] 06/10/2017 11:54

They did mention some large corporate client potential as well.

[bahiflyer] 06/10/2017 11:43

Its because the mm's have winkled out enough loose shares ready for the next leg up.
Plus of course the £ is now sliding back down against the $.

[runthejoules] 06/10/2017 11:24

It's an excuse for ADVFN to use an animation of a wasp. Seriously, why are we up 6.5% today though? Is it because no-one's sold the shares given out in options this Monday?

[trinko] 02/10/2017 13:19

What is buzz activity??

[chadders] 27/9/2017 08:03

Another thumbs up and testament to the value of Accolade. Should help with the current push onto new markets.

[chadders] 24/9/2017 14:17

From the half yearly report,

Sopheon's Chairman, Barry Mence said: "In addition to increasing both revenue and profits, we continue to build momentum and gain enhanced market recognition... full year revenue visibility for 2017 from contracted business and recurring revenue streams is already at $20.3m. In addition we have a growing sales pipeline, including several blue chip companies representing major enterprise opportunities. These factors give the Board confidence in meeting our goals for the year, and as importantly, our ambition to accelerate growth in the future. Given these positive circumstances, the Board is actively considering the introduction of a dividend policy."

Much more to come methinks

[chadders] 14/9/2017 13:41

Agreed bahiflyer. Happy to hold on to mine for much longer.

[bahiflyer] 14/9/2017 13:35

Its just a minor correction having come back up from £3.30 in a relatively short time almost exactly mirroring beginning of Feb's movement.
Next stop a fiver once this stage of profit taking is over.

[mfhmfh] 14/9/2017 12:01

Let's see if it stays above/bounces off the 200 day MA.

[gleach23] 14/9/2017 10:50

When I said I thought it would make light work of cutting through the 400s I meant up not down :{

Keeping the faith.

[gleach23] 12/9/2017 14:53

Well one could only buy 15 shares online @ 412p and the same is true now the Offer has moved to 420p which imo supports the view that it's a tree shake.

Strangely when I put a buy limit order in to my broker (AJ Bell) for 500 shares it was filled straight away @ 412p which I found a little odd.

[chadders] 12/9/2017 14:50

Yes, not surprising given the recent rise but still cheap

[runthejoules] 12/9/2017 14:08

Loks like a lunchtime tree-shake. Lot of it about.

[trinko] 11/9/2017 23:25

Why the fall first?